Protagenic Therapeutics, Inc.\new - FORM 8-K - EX-16.1 - EXHIBIT 16.1 - June 20, 2016

Attached files

file filename
EX-10.3 - EXHIBIT 10.3 - Protagenic Therapeutics, Inc.\newex10-3.htm
EX-10.2 - EXHIBIT 10.2 - Protagenic Therapeutics, Inc.\newex10-2.htm
EX-10.1 - EXHIBIT 10.1 - Protagenic Therapeutics, Inc.\newex10-1.htm
EX-3.1 - EXHIBIT 3.1 - Protagenic Therapeutics, Inc.\newex3-1.htm
EX-2.2 - EXHIBIT 2.2 - Protagenic Therapeutics, Inc.\newex2-2.htm
EX-2.1 - EXHIBIT 2.1 - Protagenic Therapeutics, Inc.\newex2-1.htm
8-K - FORM 8-K - Protagenic Therapeutics, Inc.\newatrn20160615_8k.htm

Exhibit 16.1

 

June 17, 2016

 

 

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

 

 

Ladies and Gentlemen:

 

 

We have read Item 4.01 of Form 8-K for the event that occurred on February 11, 2016, to be filed by Atrinsic, Inc. We are in agreement with the statements contained in the first sentence of the first paragraph of Item 4.01with regards to the dismissal of Schulman Lobel Zand Katzen Williams & Blackman LLP, and the second, third, fourth and fifth paragraphs of Item 4.01 in their entirety. We have no basis to agree or disagree with other statements of Atrinsic, Inc. contained in the sixth paragraph of Item 4.01 or contained in the rest of the Form 8-K document.

 

 

 

/s/ Schulman Lobel Zand Katzen Williams & Blackman LLP

Certified Public Accountants

North Brunswick, New Jersey

 

 

 

Protagenic Therapeutics, Inc.\new Reports